drugset / Trial / NCT05117476
A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
CLN-619-001 is a Phase 1, open-label, multi-center study of CLN-619 alone and in combination with pembrolizumab in patients with advanced solid tumors.
Timeline
- Start
- 2021-10-29
- Primary completion
- 2026-03
- Completion
- 2026-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CLN-619 | Monoclonal antibody | — | — |
| Subject | Datopotamab deruxtecan | Monoclonal antibody | — | — |
| Subject | Pembrolizumab | Monoclonal antibody | — | — |
| Background | Carboplatin | Small molecule | — | — |
| Background | Paclitaxel | Small molecule | — | — |
| Background | Pemetrexed | Small molecule | — | — |